ASCO2025
Advertisement
The phase 1/2 study's safety and efficacy data on bexmarilimab plus azacitidine for high-risk MDS are promising.
Mosunetuzumab’s mechanism of action involves connecting B-cells with T-cells for elimination by the immune system.
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
AI is revolutionizing oncology with faster analysis, better predictions, and more personalized cancer care.
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.
Zanubrutinib and venetoclax show deep and lasting responses in frontline CLL and SLL including those with del 17p or TP53.
A fixed duration regimen of the combination was compared with a regimen guided by measurable residual disease.
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
Dr. Andorsky discusses CML dose escalation, treatment discontinuation, and unmet needs in leukemia care.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.